Merck & Company, Inc. (NYSE:MRK) Short Interest Update

In comparing the stock’s current level to its extended history, the stock is trading -10.115% away from its 52-week high of 63.620 and +8.945% away from the stock’s low point over the past 52 weeks, which was 52.490. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The company now has a consensus rating of “Hold” and a consensus price target of $64.95.

Merck & Co. (NYSE:MRK) last released its quarterly earnings data on Tuesday, July 28th.

Company shares opened the most recent trading session at 56.510 and at the time of writing the last Bid was at 57.185.

The price to earnings ratio, or the valuation ratio of a company’s current share price compared to its per-share earnings sits at 14.857.

Merck’s Q2 earnings rose 1% over last year’s Q2 to 86 cents a share, beating consensus by 5 cents. It reported EPS of $0.85, which was $0.10 ahead of the consensus. The business had revenue of $9.80 billion for the quarter, compared to analysts’ expectations of $9.81 billion.

Other research analysts also recently issued research reports about the company. Vetr downgraded shares of Merck & Co. from a “strong-buy” rating to a “buy” rating and set a $63.46 price target on the stock.in a research note on Tuesday. Analysts at Sanford C. Bernstein raised their price target on shares of Pfizer from $38.00 to $39.00 and gave the company an “outperform” rating in a research note on Monday, July 20th.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 2nd. This represents a $1.80 dividend on an annualized basis and a yield of 3.16%. They issued a “neutral” rating and a $65.00 price target on the stock.

Sanofi agreed to pay Regeneron $640 million upfront, and the two companies will invest $1 billion in developing the drug to the proof-of-concept stage, with Sanofi contributing 75% and Regeneron 25% of the total.

In other Merck & Co. news, EVP Adam H. The stock was sold at an average price of $34.39, for a total transaction of $894,140.00. The ex-dividend date of this dividend is Friday, September 11th. Schechter offered 10,634 shares of the corporation’s inventory in a transaction that occurred on Monday, May Possibly 11th. The shares were sold at an average price of $60.44, for a total transaction of $642,718.96. Piper Jaffray began coverage on Merck & Co.in a research report on Wednesday, June 17th. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The revealing for this particular sale may be found here. It also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. The operations of the Company are principally managed on a merchandises basis and are comprised of four operating segments, which are Animal Health, the Pharmaceutical, Consumer Care and Alliances sections. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company is engaged in the discovery, development and manufacture of healthcare products.

To view Vetr’s full report, visit Vetr’s official website.